Jennifer Kruger, MD
Neurology · Rapid City, SDNPI 1396953774
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,940 of the $18,952 with a category attached, or 78.8%. 26 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 59.4% of the total. Reporting peaked in 2019 at $9,722 and has fallen 92.3% since, to $745 in 2022. Among neurology clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $104.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$11K
- AbbVie$6K
- Novartis$386
- Genentech USA, Inc.$166
- Amgen$165
- Kyowa Kirin, Inc.$75
- plus $493 from 20 others
What the payments were for
- Speaking & faculty fees$14,94079%
- Travel & lodging$7134%
- Food & beverage$2,83915%
- Education$4602%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $11,258 |
| AbbVie(2 entities) | 70 | $6,410 |
| Novartis | 28 | $386 |
| Genentech USA, Inc. | 10 | $166 |
| Amgen | 10 | $165 |
| Kyowa Kirin, Inc. | 5 | $75 |
| Acadia Pharmaceuticals Inc | 4 | $61 |
| CSL Behring | 2 | $40 |
| EMD Serono, Inc. | 3 | $39 |
| GRT US Holding, Inc. | 2 | $39 |
| SK Life Science, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Biogen | 2 | $28 |
| Bristol Myers Squibb | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| GE HealthCare | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Travere Therapeutics, Inc. | 3 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,952 in reported general payments places this provider in the 90th percentile of 49 neurology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 12 | $100,236 |
| RytaryCarbidopa/Levodopa | 56 | $88,989 |
| Nurtec OdtRimegepant Sulfate | 51 | $79,506 |
| GocovriAmantadine Hcl | 23 | $61,162 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 979 | $40,891 |
| InbrijaLevodopa | 15 | $40,315 |
| Aimovig AutoinjectorErenumab-Aooe | 46 | $38,629 |
| NeuproRotigotine | 19 | $22,459 |
| Rasagiline Mesylate | 123 | $15,710 |
| UbrelvyUbrogepant | 15 | $14,864 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 254 | $12,680 |
| Entacapone | 35 | $8,053 |
| AmantadineAmantadine Hcl | 169 | $7,143 |
| RivastigmineRivastigmine Tartrate | 84 | $6,045 |
| Primidone | 173 | $4,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $28 | $100,23612 claims |
| AbbVieUbrelvy | $6,410 | $14,86415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 neurology providers in South Dakota.
Other neurology in Rapid City
- Mohamadmostafa JahansouzRapid City$3K
- Lee McCraneyRapid City$2K
- Barbara MerrimanRapid City$2K
- Heather CwachRapid City$2K
- Brian TschidaRapid City$1K
- Robert FinleyRapid City$732
- Eunhye OakRapid City$429
- Steven HataRapid City$407
- Matthew SimmonsRapid City$250
- Robert MaclachlanRapid City$163
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.